On Thursday, AbbVie Inc. (NYSE:ABBV) reported second-quarter adjusted EPS of $2.65, down 8.9% year over year, beating the consensus of $2.57. Net revenues reached $14.46 billion, up 4.3%, beating the consensus of $14.03 billion. Sales were up 5.6% on an operational basis. Cantor Fitzgerald writes that quality 2Q24 earnings results support a positive investment thesis and increase confidence that growth will accelerate in 2025+. This high single-digit, above-market growth in 2025+ is not fully reflected in the stock’s valuation yet. The analyst reiterates the Overweight rating, with a price target of $200. Truist Securities maintains the Buy rating and increases the price target from 195 to $210. The analyst sees strong performance across AbbVie’s diversified portfolio and potential for ongoing growth into the end of ...